Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation
- PMID: 16344314
- DOI: 10.1200/JCO.2005.03.3688
Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation
Abstract
Purpose: Patients with localized esophageal carcinoma have a 5-year survival rate of less than 20%. Patients are often treated similarly (ie, with preoperative chemoradiotherapy) but the outcomes vary greatly. Chemoradiotherapy and surgery can result in significant undesirable consequences. Currently, however, there are no tools to help select optimum therapy. We hypothesized that gene expression profiling could provide clues and biomarkers for selection of therapy.
Methods: Pretreatment endoscopic cancer biopsies from 19 patients (16 with adenocarcinoma, two with squamous cell carcinoma, and one with adenosquamous carcinoma) enrolled onto a preoperative chemoradiotherapy protocol were profiled using oligonucleotide microarrays. Surgical specimens following therapy were assessed for the degree of pathologic response. On the basis of array data, selected genes were analyzed by polymerase chain reaction.
Results: Unsupervised hierarchical cluster analysis segregated the cancers into two molecular subtypes, each consisting 10 and nine specimens, respectively. Most cancers (five of six) that had pathologic complete response (pathCR) clustered in molecular subtype I. Subtype II, with one exception, consisted cancers that had less than pathCR (< pathCR). Using a combination marker approach, levels of PERP, S100A2, and SPRR3 allowed discrimination of pathCR from < pathCR with high sensitivity and specificity (85%). Pathway analysis identified apoptotic pathway as one of the key functions downregulated in molecular type II in comparison with type I.
Conclusion: These encouraging, albeit preliminary, data suggest that expression profiling may distinguish cancers with different pathologic outcome. This is the first report to show subtypes of esophageal cancers with distinct molecular signatures. The potential of PERP, S100A2, and SPRR3 as biomarkers of pathCR warrants further validation.
Similar articles
-
Biomarkers of response to preoperative chemoradiation in esophageal cancers.Semin Oncol. 2006 Dec;33(6 Suppl 11):S2-5. doi: 10.1053/j.seminoncol.2006.10.004. Semin Oncol. 2006. PMID: 17178277 Review.
-
Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers.Clin Cancer Res. 2007 Feb 1;13(3):912-9. doi: 10.1158/1078-0432.CCR-06-1577. Clin Cancer Res. 2007. PMID: 17289885
-
Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response.Cancer. 2005 Dec 1;104(11):2365-72. doi: 10.1002/cncr.21439. Cancer. 2005. PMID: 16245310
-
Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.J Clin Oncol. 2005 Feb 20;23(6):1237-44. doi: 10.1200/JCO.2005.01.305. J Clin Oncol. 2005. PMID: 15718321 Clinical Trial.
-
Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts.J Clin Oncol. 2006 Nov 1;24(31):5079-90. doi: 10.1200/JCO.2005.05.1748. J Clin Oncol. 2006. PMID: 17075127 Review.
Cited by
-
Loss of the p53/p63 target PERP is an early event in oral carcinogenesis and correlates with higher rate of local relapse.Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jan;115(1):95-103. doi: 10.1016/j.oooo.2012.10.017. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013. PMID: 23217540 Free PMC article.
-
An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma.Signal Transduct Target Ther. 2020 Sep 4;5(1):182. doi: 10.1038/s41392-020-00221-8. Signal Transduct Target Ther. 2020. PMID: 32883946 Free PMC article.
-
Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.Gastrointest Cancer Res. 2012 Mar;5(2):49-57. Gastrointest Cancer Res. 2012. PMID: 22690258 Free PMC article.
-
Identification of immune-related genes contributing to head and neck squamous cell carcinoma development using weighted gene co-expression network analysis.Cancer Rep (Hoboken). 2023 May;6(5):e1808. doi: 10.1002/cnr2.1808. Epub 2023 Apr 24. Cancer Rep (Hoboken). 2023. PMID: 37092360 Free PMC article.
-
Predictive genetic markers in neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: a long way to go. Review of the literature.Pharmacogenomics J. 2018 Jan;18(1):14-22. doi: 10.1038/tpj.2017.25. Epub 2017 Jun 13. Pharmacogenomics J. 2018. PMID: 28607505 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous